KURN Stock Overview
A biopharmaceutical company, engages in the commercialization and development for tissue repair and bone regeneration in the United States, the European Union, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Kuros Biosciences AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 20.10 |
| 52 Week High | CHF 32.00 |
| 52 Week Low | CHF 3.06 |
| Beta | 0.78 |
| 1 Month Change | -17.28% |
| 3 Month Change | 1.93% |
| 1 Year Change | 443.24% |
| 3 Year Change | 960.69% |
| 5 Year Change | 730.58% |
| Change since IPO | -33.00% |
Recent News & Updates
Kuros Biosciences AG's (VTX:KURN) 27% Share Price Plunge Could Signal Some Risk
Dec 13
Kuros Biosciences (VTX:KURN) Is In A Strong Position To Grow Its Business
Nov 28Kuros Biosciences AG's (VTX:KURN) Shares Climb 30% But Its Business Is Yet to Catch Up
Oct 24Market Participants Recognise Kuros Biosciences AG's (VTX:KURN) Revenues Pushing Shares 37% Higher
Aug 22Recent updates
Kuros Biosciences AG's (VTX:KURN) 27% Share Price Plunge Could Signal Some Risk
Dec 13Kuros Biosciences (VTX:KURN) Is In A Strong Position To Grow Its Business
Nov 28Kuros Biosciences AG's (VTX:KURN) Shares Climb 30% But Its Business Is Yet to Catch Up
Oct 24Market Participants Recognise Kuros Biosciences AG's (VTX:KURN) Revenues Pushing Shares 37% Higher
Aug 22We Think Kuros Biosciences (VTX:KURN) Can Afford To Drive Business Growth
Jul 16Kuros Biosciences AG (VTX:KURN) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable
May 30Why Investors Shouldn't Be Surprised By Kuros Biosciences AG's (VTX:KURN) 35% Share Price Surge
Apr 11Some Confidence Is Lacking In Kuros Biosciences AG (VTX:KURN) As Shares Slide 29%
Jan 03Companies Like Kuros Biosciences (VTX:KURN) Are In A Position To Invest In Growth
Dec 17We Think Kuros Biosciences (VTX:KURN) Can Afford To Drive Business Growth
Sep 17Market Cool On Kuros Biosciences AG's (VTX:KURN) Revenues
Jun 28Here's Why We're Not At All Concerned With Kuros Biosciences' (VTX:KURN) Cash Burn Situation
May 03Companies Like Kuros Biosciences (VTX:KURN) Are In A Position To Invest In Growth
Jun 11Shareholders May Find It Hard To Justify Increasing Kuros Biosciences AG's (VTX:KURN) CEO Compensation For Now
Apr 12Reflecting on Kuros Biosciences' (VTX:KURN) Share Price Returns Over The Last Five Years
Mar 02What We Learned About Kuros Biosciences' (VTX:KURN) CEO Pay
Nov 17
Shareholder Returns
| KURN | CH Biotechs | CH Market | |
|---|---|---|---|
| 7D | -2.9% | -0.6% | -2.3% |
| 1Y | 443.2% | 88.9% | 0.7% |
Return vs Industry: KURN exceeded the Swiss Biotechs industry which returned 88.9% over the past year.
Return vs Market: KURN exceeded the Swiss Market which returned 0.7% over the past year.
Price Volatility
| KURN volatility | |
|---|---|
| KURN Average Weekly Movement | 12.6% |
| Biotechs Industry Average Movement | 12.6% |
| Market Average Movement | 3.2% |
| 10% most volatile stocks in CH Market | 7.4% |
| 10% least volatile stocks in CH Market | 1.6% |
Stable Share Price: KURN's share price has been volatile over the past 3 months compared to the Swiss market.
Volatility Over Time: KURN's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Swiss stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 106 | Chris Fair | www.kuros.ch |
Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development for tissue repair and bone regeneration in the United States, the European Union, and internationally. It operates through three segments: Medical Devices, Pharmaceuticals, and Legacy Portfolio. The company offers MagnetOs Granules, an original advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology; MagnetOs Putty, a mold use to fill bony voids for a predictable fusion; MagnetOs Easypack Putty, a ready-to-use mold to be implanted in any intervertebral disc space or posterolateral spine level; and Magnetos Flex Matrix, an open matrix bone graft.
Kuros Biosciences AG Fundamentals Summary
| KURN fundamental statistics | |
|---|---|
| Market cap | CHF 755.22m |
| Earnings (TTM) | -CHF 8.89m |
| Revenue (TTM) | CHF 52.54m |
14.4x
P/S Ratio-85.0x
P/E RatioIs KURN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KURN income statement (TTM) | |
|---|---|
| Revenue | CHF 52.54m |
| Cost of Revenue | CHF 6.43m |
| Gross Profit | CHF 46.11m |
| Other Expenses | CHF 55.00m |
| Earnings | -CHF 8.89m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.24 |
| Gross Margin | 87.77% |
| Net Profit Margin | -16.91% |
| Debt/Equity Ratio | 0% |
How did KURN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 03:02 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kuros Biosciences AG is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Laura Pfeifer-Rossi | Bank am Bellevue |
| Olav Zilian | Mirabaud Securities Limited |
| Dylan van Haaften | NIBC Bank N.V. |